GenEng News  Apr 20  Comment 
Eisai subsidiary H3 Biomedicine said today it has extended its more than 2-year-old collaboration with Foundation Medicine to discover and develop precision medicines in oncology. The value of the expanded collaboration was not disclosed. ...
Motley Fool  Apr 10  Comment 
The company has selected a new CEO, and that CEO's track record is sparking optimism.
GenEng News  Apr 5  Comment 
Meiji Seika Pharma granted Eisai exclusive rights to commercialize the Parkinson’s disease drug, safinaminde, in Japan, South Korea, Taiwan, Brunei, Cambodia, Laos, Malaysia, and the Philippines. Meiji is developing the selective monoamine...
FierceBiotech  Mar 31  Comment 
Merck KGaA spinoff licenses IBD drug to Eisai joint venture nptaylor Fri, 03/31/2017 - 04:27
Motley Fool  Mar 15  Comment 
The biopharma's shares soared by double-digits Wednesday on a strong Q4 earnings release.
SeekingAlpha  Feb 2  Comment 
FiercePharma  Jan 27  Comment 
FiercePharmaAsia: WuXi AppTec subsidiary’s IPO, Mezzion’s lawsuit against Dr. Reddy’s, Eisai’s liver cancer med, and more aliu Fri, 01/27/2017 - 08:52
FiercePharma  Jan 25  Comment 
Eisai's Lenvima moves toward Nexavar showdown with phase 3 liver cancer win chelfand Wed, 01/25/2017 - 10:36

You may also be interested in articles related to Eisai Co. Ltd. (ESALY):


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki